UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

(Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said ...

As Pfizer offers the British government promises to protect the UK research base in order to smooth its planned takeover of AstraZeneca ... that both research and development stay in Sweden ...

Partex's platform will provide comprehensive analyses, including target identification, indication expansion, and molecular profiling, ultimately accelerating the process of bringing innovative ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors�reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

They are solving some of the current challenges in cybersecurity and imaging to protect people and organizations. Through research, RIT is making an impact. RIT is one of the top universities in the ...

The "Innovation Insights: Engineered Exosomes" report has been added to ResearchAndMarkets.com's offering. In the Engineered Exosome drug deals, there have been 77 deals totaling US$5.1 billion, with ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.